CRINETICS PHARMACEUTICALS INC. - COMMON STOCK

Crinetics Pharmaceuticals Appoints Dana Pizzuti, M.D. as Chief Development Officer

03 Oct 2022 08:00:01 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

12 Sep 2022 08:00:01 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

08 Sep 2022 08:00:01 By Nasdaq GlobeNewswire

New Long-Term Safety and Efficacy Data Presented with Paltusotine in Participants Living with Acromegaly

06 Sep 2022 08:00:02 By Nasdaq GlobeNewswire

New Long-Term Safety and Efficacy Data for Investigational Compound Paltusotine to be Presented at the Brazilian Congress of Endocrinology and Metabolism

02 Sep 2022 08:00:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

12 Aug 2022 08:00:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 Aug 2022 16:44:12 By Nasdaq GlobeNewswire

Additional Analyses of CRN04894 Preclinical and Phase 1 Results to be Presented at the 10th International Congress of Neuroendocrinology

04 Aug 2022 08:00:01 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

12 Jul 2022 17:09:22 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 Jun 2022 16:30:47 By Nasdaq GlobeNewswire

Crinetics Presents Clinical and Research Results at ENDO 2022

08 Jun 2022 07:30:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals to Participate in the JMP Securities Life Sciences Conference

07 Jun 2022 07:30:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Reports Positive Top-line Results Including Strong Adrenal Suppression from CRN04894 Phase 1 Study Multiple-Ascending Dose Cohorts

25 May 2022 07:00:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

12 May 2022 16:41:57 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 May 2022 16:18:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Closing of Underwritten Common Stock Offering

18 Apr 2022 16:01:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Pricing of Underwritten Common Stock Offering

12 Apr 2022 23:52:43 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11 Apr 2022 17:15:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results

30 Mar 2022 16:02:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Reports Positive Top-Line Results from CRN04777 Phase 1 Study Multiple-Ascending Dose Cohorts

30 Mar 2022 16:01:00 By Nasdaq GlobeNewswire